



NEWS RELEASE

## BIOSYENT TO ATTEND PLANET MICROCAP SHOWCASE

FOR IMMEDIATE RELEASE

APRIL 14, 2025

**MISSISSAUGA, ONTARIO (April 14, 2025)** BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase: VEGAS 2025 investor conference in Las Vegas, Nevada from April 22<sup>nd</sup> to April 24<sup>th</sup>, 2025 at the Paris Hotel & Casino. Mr. René Goehrums, President and CEO of BioSyent, will be presenting in person to attendees at the conference on Wednesday, April 23<sup>rd</sup> from 12:30pm to 1:00pm PDT in Track 2 – Bordeaux.

Mr. Goehrums will also be meeting with investors on a one-on-one basis during the conference on Wednesday, April 23<sup>rd</sup> between 1:30pm - 6:00pm PDT and on Thursday, April 24<sup>th</sup> between 8:00am – 5:00pm PDT. Subject to availability, these one-on-one meetings can be requested by registered attendees through the conference portal online: [https://www.meetmax.com/sched/event\\_113149/conference\\_home.html](https://www.meetmax.com/sched/event_113149/conference_home.html).

### About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty, and international business units.

As of the date of this press release, the Company has 11,254,638 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit [www.tmxmoney.com](http://www.tmxmoney.com).

### For further information please contact:

Mr. René C. Goehrums  
President and CEO  
BioSyent Inc.  
E-Mail: [investors@biosyent.com](mailto:investors@biosyent.com)  
Phone: 905-206-0013  
Web: [www.biosyent.com](http://www.biosyent.com)

*This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.*

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.*